Antibody landscapes after influenza virus infection or vaccination JM Fonville, SH Wilks, SL James, A Fox, M Ventresca, M Aban, L Xue, ... Science 346 (6212), 996-1000, 2014 | 445 | 2014 |
Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands R Bodewes, G de Mutsert, FRM Van Der Klis, M Ventresca, S Wilks, ... Clinical and Vaccine Immunology 18 (3), 469-476, 2011 | 174 | 2011 |
Defining the risk of SARS-CoV-2 variants on immune protection MM DeGrace, E Ghedin, MB Frieman, F Krammer, A Grifoni, A Alisoltani, ... Nature 605 (7911), 640-652, 2022 | 136 | 2022 |
A review of influenza haemagglutinin receptor binding as it relates to pandemic properties S Wilks, M de Graaf, DJ Smith, DF Burke Vaccine 30 (29), 4369-4376, 2012 | 91 | 2012 |
Mapping SARS-CoV-2 antigenic relationships and serological responses SH Wilks, B Mühlemann, X Shen, S Türeli, EB LeGresley, A Netzl, ... Science 382 (6666), eadj0070, 2023 | 73 | 2023 |
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains B Ying, B Whitener, LA VanBlargan, AO Hassan, S Shrihari, CY Liang, ... Science translational medicine 14 (630), eabm3302, 2021 | 67 | 2021 |
Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant DL Gordon, D Sajkov, Y Honda-Okubo, SH Wilks, M Aban, IG Barr, ... Vaccine 34 (33), 3780-3786, 2016 | 61 | 2016 |
BA. 2 and BA. 5 omicron differ immunologically from both BA. 1 omicron and pre-omicron variants A Rössler, A Netzl, L Knabl, H Schäfer, SH Wilks, D Bante, ... Nature communications 13 (1), 7701, 2022 | 54 | 2022 |
Antigenic maps of influenza A (H3N2) produced with human antisera obtained after primary infection JM Fonville, PLA Fraaij, G de Mutsert, SH Wilks, R van Beek, ... The Journal of infectious diseases 213 (1), 31-38, 2016 | 39 | 2016 |
SARS-CoV-2 variant vaccine boosters trial: preliminary analyses AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ... MedRxiv, 2022.07. 12.22277336, 2022 | 34 | 2022 |
Influenza virus infection history shapes antibody responses to influenza vaccination M Auladell, HVM Phuong, LTQ Mai, YY Tseng, L Carolan, S Wilks, ... Nature medicine 28 (2), 363-372, 2022 | 34 | 2022 |
Analysis of SARS-CoV-2 omicron neutralization data up to 2021-12-22 A Netzl, S Tureli, E LeGresley, B Mühlemann, SH Wilks, DJ Smith BioRxiv, 2021.12. 31.474032, 2022 | 22 | 2022 |
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ... Nature medicine 29 (9), 2334-2346, 2023 | 12 | 2023 |
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography A Rössler, A Netzl, L Knabl, D Bante, SH Wilks, W Borena, D Von Laer, ... Nature Communications 14 (1), 5224, 2023 | 12 | 2023 |
Bivalent and monovalent SARS-CoV-2 variant vaccine boosters improve coverage of the known antigenic landscape: results of the COVID-19 variant immunologic landscape (COVAIL) trial A Branche, N Rouphael, D Diemert, A Falsey, C Losada, LR Baden, ... Research Square, 2023 | 3 | 2023 |
Influenza virus infection history drives and shapes antibody responses to influenza vaccination A Fox, M Auladell, H Phuong, MQ Le, YY Tseng, L Carolan, S Wilks, ... | 1 | 2021 |
Visualisation and analysis of patterns in serological data using" antibody landscapes" SH Wilks | 1 | 2018 |
Antigenic maps of influenza A/H3N2 virus produced with human antisera obtained after primary infection JM Fonville, PLA Fraaij, G de Mutsert, SH Wilks, R van Beek, ... J Infect Dis, 2015 | 1 | 2015 |
Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays B Mühlemann, SH Wilks, L Baracco, M Bekliz, JM Carreño, VM Corman, ... Science Translational Medicine 16 (747), eadl1722, 2024 | | 2024 |
Characterization of A/H7 influenza virus global antigenic diversity and key determinants in the hemagglutinin globular head mediating A/H7N9 antigenic evolution A Kok, R Scheuer, TM Bestebroer, DF Burke, SH Wilks, MI Spronken, ... Mbio 14 (5), e00488-23, 2023 | | 2023 |